NCT02932462

Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis

A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site, Phase III Clinical Study to Evaluate the Efficacy and Safety of DSXS 1535 in Patients With Mild to Severe Scalp Psoriasis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 373 (actual)
• Sponsor: Sun Pharmaceutical Industries, Inc. · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

A Randomized Double-Blind, Vehicle-Controlled, Parallel Design, Multiple-Site, Phase III Clinical Study

Detailed description

This randomized, double-blind, vehicle-controlled, parallel-group multiple-site study is designed to evaluate the therapeutic efficacy and safety of the investigational product, DSXS 1535 product, for the treatment of mild to severe scalp psoriasis

Conditions

• Scalp Psoriasis

Interventions

Type	Name	Description
DRUG	DSXS	topical product
DRUG	Placebo	topical product

Timeline

• Start date: 2016-03-01
• Primary completion: 2016-12-01
• Completion: 2017-09-29
• First posted: 2016-10-13
• Last updated: 2018-12-06
• Results posted: 2018-12-06

Regulatory

• FDA-regulated drug study